Identification of SARS-CoV-2 Variants of Concern Using Amplicon Next-Generation Sequencing.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
31 08 2022
Historique:
pubmed: 28 6 2022
medline: 9 9 2022
entrez: 27 6 2022
Statut: ppublish

Résumé

COVID-19 is caused by SARS-CoV-2, several virulent variants of which have emerged since 2019. More than 529 million people have been infected, and at least 6 million have died. Our aim was to develop a fast, accurate, low-cost method for detecting and identifying newly emerging variants of concern (VOCs) that could pose a global threat. The 341-bp DNA sequence of a specific region of the SARS-CoV-2's spike protein was amplified by a one-step PCR on RNA samples from 46 patients. The product was sequenced using next-generation sequencing (NGS). DNA sequences from seven genomes, the original Wuhan isolate and six different representative variants obtained from the GISAID website, were used as references. Complete whole-genome sequences from local isolates were also obtained from the GISAID website, and their RNA was used for comparison. We used an amplicon-based NGS method (termed VOC-NGS) for genotyping and successfully identified all 46 samples. Fifteen (32.6%) were like the original isolate. Twenty-seven were VOCs: nine (19.5%) Alpha, eight (19%) Delta, six (14%) Beta, and four (8.7%) Omicron. Two were variants of interest (VOI): one (2%) Kappa and one (2%) Zeta. Two samples were mixtures of two variants, one of Alpha and Beta and one of Alpha and Delta. The Spearman correlation between whole-genome sequencing (WGS) and VOC-NGS was significant (

Identifiants

pubmed: 35758686
doi: 10.1128/spectrum.00736-22
pmc: PMC9430688
doi:

Substances chimiques

Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0073622

Références

Nucleic Acids Res. 1988 Nov 25;16(22):10881-90
pubmed: 2849754
Genome Med. 2021 Feb 9;13(1):21
pubmed: 33563320
Nucleic Acids Res. 2018 Jul 2;46(W1):W537-W544
pubmed: 29790989
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Virology. 2021 Oct;562:63-73
pubmed: 34265628
Life Sci. 2020 Sep 15;257:118056
pubmed: 32645344
Front Cell Infect Microbiol. 2020 Nov 25;10:587269
pubmed: 33324574
Bioinformatics. 2019 Mar 1;35(5):871-873
pubmed: 30124794
Nat Microbiol. 2021 Jul;6(7):821-823
pubmed: 34108654
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Pathogens. 2021 May 21;10(6):
pubmed: 34064143
J Biol Chem. 2020 Dec 25;295(52):18579-18588
pubmed: 33122196
PLoS One. 2021 Feb 17;16(2):e0247115
pubmed: 33596239
Pathogens. 2020 Jul 13;9(7):
pubmed: 32668692
J Infect Chemother. 2021 Sep;27(9):1336-1341
pubmed: 34154921
Cell. 2021 Jun 24;184(13):3426-3437.e8
pubmed: 33991487
Rev Med Virol. 2021 Nov;31(6):e2231
pubmed: 33724631
J Travel Med. 2021 Oct 11;28(7):
pubmed: 34230972
Nat Commun. 2021 Dec 13;12(1):7251
pubmed: 34903718
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Front Cell Infect Microbiol. 2021 May 20;11:672562
pubmed: 34123874
Cell. 2021 Apr 29;184(9):2523
pubmed: 33930298
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Infect Genet Evol. 2021 Aug;92:104869
pubmed: 33915216
Front Med (Lausanne). 2022 Feb 22;9:815389
pubmed: 35273977

Auteurs

Abdelmajeed Nasereddin (A)

Head of the Genomics Applications Laboratory, Core Research Facility, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Hadar Golan Berman (H)

Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Dana G Wolf (DG)

Clinical Virology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Esther Oiknine-Djian (E)

Clinical Virology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Sheera Adar (S)

Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH